CLOVER BIO-B (02197) announced that on March 27, 2026, the company granted a total of 10.1955 million share options and 8.965 million restricted share units to certain eligible participants under the terms of its post-IPO share option scheme and restricted share unit plan, respectively.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments